What drove the GANGAPHARM.BO stock jump on 23 Jan 2026?

The stock gap-up to **INR 13.97** came without a major corporate announcement, driven mainly by momentum and low-float buying. Volume of **8,000.00** exceeded the average **645.00**, indicating retail-led interest.

What is Meyka AI's forecast and upside for GANGAPHARM.BO stock?

Meyka AI's forecast model projects **INR 18.89** yearly for GANGAPHARM.BO stock, implying an upside of **35.18%** from **INR 13.97**. These projections are model-based and not guarantees.

How do Ganga Pharmaceuticals' fundamentals affect GANGAPHARM.BO stock valuation?

High trailing PE (**127.00**) and low EPS (**INR 0.11**) inflate valuation. Strong current ratio (**4.28**) is a positive, but negative operating cash flow raises sustainability concerns.

Is GANGAPHARM.BO stock liquid enough for large trades?

No. With market cap near **INR 82.58 million** and average volume **645.00**, liquidity is limited. Large orders could move the price significantly, increasing execution risk.

IN Stocks

GANGAPHARM.BO up 18.39% to INR 13.97 on BSE 23 Jan 2026: Top gainer outlook

ByHuzaifa Zahoor January 23, 2026

GANGAPHARM.BO stock led BSE gainers on 23 Jan 2026, jumping 18.39% to close at INR 13.97. Volume was 8,000 shares, well above the 645.00 average volume, signaling strong intraday interest. The move followed no major new release, so trading appears driven by momentum and small-cap rotation in the Healthcare sector in India. We review price action, fundamentals, technicals, and a Meyka AI forecast to frame the near-term opportunity and risks.